Accéder au contenu
Merck

Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature.

The American journal of the medical sciences (2001-10-27)
A Schattner, N Kozak, J Friedman
RÉSUMÉ

Two elderly patients, treated with captopril for left ventricular dysfunction and diabetes, developed severe cholestatic jaundice for which no alternative explanation could be found. The jaundice resolved completely after discontinuation of the drug. A review of the literature identifies a highly similar and distinctive clinical pattern in another 13 cases reported and suggests that hepatotoxicity is a well-established yet rare adverse effect of captopril. However, the very common use of this drug, together with the severity of the liver injury it may cause, calls for a high index of suspicion and increased awareness of this phenomenon.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Captopril, ≥98% (HPLC), powder
Supelco
Captopril, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Captopril, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Captopril, meets USP testing specifications
Captopril, European Pharmacopoeia (EP) Reference Standard
Captopril for system suitability, European Pharmacopoeia (EP) Reference Standard